Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, and many patients have benefited from its use. To date, six CAR T-cell products have been approved by the FDA and EMA, and many more are being developed and investigated in clinical trials. The whole field of adoptive cell transfer has experienced an unbelievable development process, and we are now at the edge of a new era of immune therapies that will have its impact beyond hematologic malignancies. Areas of interest are, e.g., solid oncology, autoimmune diseases, infectious diseases, and others. Although much has been achieved so far, there is still a huge effort needed to overcome significant challenges and difficulties. We are witnessing a rapid expansion of knowledge, induced by new biomedical technologies and CAR designs. The era of CAR T-cell therapy has just begun, and new products will widen the therapeutic landscape in the future. This review provides a comprehensive overview of the clinical applications of CAR T-cells, focusing on the approved products and emphasizing their benefits but also indicating limitations and challenges.
嵌合抗原受体（CAR）T细胞疗法已成为B细胞和浆细胞恶性肿瘤的重要治疗选择，众多患者从中获益。截至目前，已有六款CAR-T细胞产品获得美国食品药品监督管理局和欧洲药品管理局批准，更多产品正处于临床试验研发阶段。过继性细胞治疗领域经历了令人瞩目的发展历程，我们正站在免疫治疗新时代的前沿，其影响将超越血液系统恶性肿瘤范畴。当前研究热点已拓展至实体肿瘤、自身免疫性疾病、感染性疾病等领域。尽管已取得显著成果，但仍需付出巨大努力以应对重大挑战与困难。在新型生物医学技术与CAR设计的推动下，该领域知识体系正快速扩展。CAR-T细胞治疗时代刚刚开启，未来新产品将持续拓展治疗疆界。本综述系统阐述CAR-T细胞的临床应用，重点分析已获批产品的疗效优势，同时指出其局限性与现存挑战。
肿瘤(癌症)患者之家